43.70
-0.5(-1.13%)
Currency In USD
| Previous Close | 44.2 |
| Open | 44.57 |
| Day High | 44.57 |
| Day Low | 43.21 |
| 52-Week High | 53.27 |
| 52-Week Low | 19.45 |
| Volume | 584,789 |
| Average Volume | 873,998 |
| Market Cap | 3.07B |
| PE | -14.05 |
| EPS | -3.11 |
| Moving Average 50 Days | 42.45 |
| Moving Average 200 Days | 39.25 |
| Change | -0.5 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,313.89 as of July 30, 2025 at a share price of $43.7. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 2 years ago, it would be worth $2,034.45 as of July 30, 2025 at a share price of $43.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
GlobeNewswire Inc.
Jun 27, 2025 3:56 AM GMT
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the
Kymera Therapeutics Announces Proposed Public Offering
GlobeNewswire Inc.
Jun 25, 2025 8:05 PM GMT
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced tha
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
GlobeNewswire Inc.
Jun 25, 2025 11:05 AM GMT
Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety prof